Dominic Adair and Gregory Bacon have been quoted in FirstWord Pharma on recent developments in pending biosimilar Humira litigation in the UK. These relate to the potential ability of a party to ‘clear the way’ prior to launch by seeking so-called Arrow declarations regarding pending patent applications. This is an issue of particular interest to companies operating in the pharmaceutical sector where interim injunctions are often sought to restrain the launch of generic (and increasingly biosimilar) products pending trial, and the interest of generic and biosimilar manufacturers in obtaining commercial certainty in advance regarding patent applications that are pending but may grant before launch.
Read full article here.